NCT07737951 Tai Chi for Reducing Aromatase Inhibitor-Induced Arthralgia
| NCT ID | NCT07737951 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Thomas Jefferson University |
| Condition | Hormone Receptor Positive Breast Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-07-27 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2026-07-27 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of the pilot RCT is to evaluate the feasibility and acceptability of a Tai Chi intervention "TaiChi4Joint" vs. an HE AC group for relieving AIIA in women with hormone receptor positive stage I-III BCa. The investigators will pilot test our data collection for mechanism measures via three innovatively integrated biobehavioral pathways.
Eligibility Criteria
Inclusion Criteria: -Individuals must meet all the following inclusion criteria in order to be eligible to participate in the study: * Age ≥18 years * Diagnosis of stage I-III hormone receptor-positive breast cancer * Postmenopausal * Currently receiving an aromatase inhibitor (anastrozole, letrozole, or exemestane) or within 5 years of initiation * Report joint pain that started or worsened after initiation of AI therapy * Report worst pain in the past week ≥3 on the BPI (0-10 scale) * Able to complete study procedures in English * Willing to be randomized to an intervention or attention control group and adhere to study procedures Exclusion Criteria: -An individual who meets any of the following criteria will be excluded from participation in this study: * Undergoing active cancer treatment (excluding endocrine therapy) * Uncontrolled cardiac or pulmonary disease that would limit safe participation * Currently engaged in regular structured moderate- or vigorous-intensity exercise (e.g., brisk walking, jogging/running, cycling, swimming, aerobic classes, or resistance training) totaling ≥150 minutes per week over the past 3 months * Currently participating in Tai Chi, yoga, Pilates, or other structured mind-body practice ≥2 times per week over the past 3 months * Joint pain due to inflammatory arthritic conditions * Recent surgery or joint injection within the past 4-6 weeks * Initiation or dose change of corticosteroids or opioids within the past 4 weeks * Planned discontinuation of AI therapy within the next 6 months * This study is limited to women with breast cancer, as \<1% of cases occur in men and data on AIIA in male patients are limited
Contact & Investigator
Kuang-Yi Wen, PhD
PRINCIPAL INVESTIGATOR
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Frequently Asked Questions
Who can join the NCT07737951 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Hormone Receptor Positive Breast Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07737951 currently recruiting?
Yes, NCT07737951 is actively recruiting participants. Contact the research team at Kuang-Yi.Wen@Jefferson.edu for enrollment information.
Where is the NCT07737951 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT07737951 clinical trial?
NCT07737951 is sponsored by Thomas Jefferson University. The principal investigator is Kuang-Yi Wen, PhD at Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The trial plans to enroll 40 participants.